Form 4: HeartSciences Inc. Executive Granted Stock Options

HeartSciences Inc. Chief Operating Officer Mark T. Hilz was granted 45,000 stock options, vesting over time and upon FDA regulatory clearance.

Summary

• Mark T. Hilz, Chief Operating Officer of HeartSciences Inc., was granted 45,000 employee stock options.
• The options have an exercise price of $3.33 per share.
• The grant was effective as of January 16, 2025.
• One-third of the options will vest on January 16, 2026.
• The remaining options will vest in increments of 8.333% every three months thereafter for the next seven quarters.
• Full vesting is also contingent on the company receiving FDA regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm.
• The options expire ten years from the effective date, on January 16, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. The vesting is tied to regulatory approval which is a positive sign of confidence in the company's future.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued employment and achievement of regulatory milestones.

Risks

• The vesting of the options is contingent on FDA regulatory clearance, which is not guaranteed.
• The value of the options is dependent on the future stock price of HeartSciences Inc.

Future Outlook

The vesting of the options is tied to the company's success in obtaining FDA regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm, which is a key milestone for the company.

Management Comments

• The options were granted pursuant to the approval of the compensation committee of the Issuer's board of directors.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and medical device industries, aligning management's interests with the company's long-term success and regulatory milestones.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry, similar to companies like Medtronic or Boston Scientific.
• The vesting schedule, tied to both time and regulatory milestones, is also a common approach to ensure long-term commitment and performance.
• The exercise price of $3.33 is specific to HeartSciences Inc. and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of management's commitment to the company's success.
• Employees may be motivated by the potential for future stock option grants.

Next Steps

• The executive will need to continue employment with the company to vest in the options.
• The company will need to obtain FDA regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm for full vesting to occur.

Key Dates

Keywords

stock options, executive compensation, vesting, FDA clearance, HeartSciences Inc., MyoVista wavECG, AI-ECG, regulatory approval